|
注册号: Registration number: |
ChiCTR2400086978 |
|
最近更新日期: Date of Last Refreshed on: |
2024-07-16 14:29:43 |
|
注册时间: Date of Registration: |
2024-07-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
一项关于结肠恶性肿瘤患者围术期FRAS(Fastest Recovery After Surgery )治疗的单中心随机对照试验 |
|
Public title: |
A Single-Center Randomized Controlled Trial on the Perioperative FRAS (Fastest Recovery After Surgery) Treatment for Patients with Malignant Colorectal Tumors |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
一项关于结肠恶性肿瘤患者围术期FRAS(Fastest Recovery After Surgery )治疗的单中心随机对照试验 |
|
Scientific title: |
A Single-Center Randomized Controlled Trial on the Perioperative FRAS (Fastest Recovery After Surgery) Treatment for Patients with Malignant Colorectal Tumors |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李瑞 |
研究负责人: |
涂小煌 |
|
Applicant: |
Rui Li |
Study leader: |
Xiaohuang Tu |
|
申请注册联系人电话: Applicant telephone: |
+86 130 3242 3166 |
研究负责人电话:
Study leader's |
+86 138 0951 7844 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
597931282@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
tuxiaohuang@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市虹口区三门路1279号 |
研究负责人通讯地址: |
上海市虹口区三门路1279号 |
|
Applicant address: |
1279 Sanmen Road, Hongkou District, Shanghai, China |
Study leader's address: |
1279 Sanmen Road, Hongkou District, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
同济大学附属上海市第四人民医院 |
||
|
Applicant's institution: |
Shanghai Fourth People's Hospital Affiliated to Tongji University |
||
|
研究负责人所在单位: |
同济大学附属上海市第四人民医院 |
||
|
Affiliation of the Leader: |
Shanghai Fourth People's Hospital Affiliated to Tongji University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024171-001 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
同济大学附属上海市第四人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Shanghai Fourth People's Hospital Affiliated to Tongji University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-07-16 00:00:00 | ||
|
伦理委员会联系人: |
薛永芳 |
||
|
Contact Name of the ethic committee: |
Yongfang Xue |
||
|
伦理委员会联系地址: |
上海市虹口区三门路1279号 A727室 |
||
|
Contact Address of the ethic committee: |
Room A727, No. 1279 Sanmen Road, Hongkou District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 55603999 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
同济大学附属上海市第四人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai Fourth People's Hospital Affiliated to Tongji University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市虹口区三门路1279号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1279 Sanmen Road, Hongkou District, Shanghai, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
同济大学附属上海市第四人民医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
1279 Sanmen Road, Hongkou District, Shanghai, China |
||||||||||||||||||||||
|
研究疾病: |
结肠恶性肿瘤 |
||||||||||||||||||||||
|
Target disease: |
Malignant Colon Tumor |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
针对结肠恶性肿瘤手术的患者,我们提出了一项极速康复Fastest Recovery After Surgery(FRAS)的改良方案,通过优化围术期麻醉、手术、护理的精细治疗,力求在保证患者诊疗安全的前提下,缩短患者的禁食时间,达到极速康复出院的治疗效果。本研究为一项前瞻性、单中心随机对照试验,意在证明与ERAS(快速康复)方案相比,FRAS(极速康复)治疗方案可以明显的缩短住院时间,有效改善患者围术期的治疗体验,且不增术后并发症的发生几率,为FRAS(极速康复)治疗方案的推广提供科学可信的证据支持。 |
||||||||||||||||||||||
|
Objectives of Study: |
For patients undergoing surgery for malignant colon tumors, we have proposed an improved Fastest Recovery After Surgery (FRAS) protocol. This protocol optimizes perioperative anesthesia, surgery, and meticulous care, aiming to ensure patient safety while reducing fasting time and achieving rapid recovery and discharge. This study is a prospective, single-center randomized controlled trial intended to demonstrate that the FRAS protocol can significantly shorten hospital stays and improve the perioperative treatment experience compared to the ERAS (Enhanced Recovery After Surgery) protocol, without increasing the incidence of postoperative complications. The study aims to provide scientifically credible evidence supporting the promotion of the FRAS protocol. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.临床影像学诊断为ⅢC期/Ⅳ期的晚期结肠恶性肿瘤 2.既往腹部手术史(腹腔内粘连严重) 3.入院时有明显消化道梗阻临床表现 4.入院时有严重影响血糖异常的内分泌系统疾病 5.入院时有严重心脑血管疾病及脏器功能不全 6.一般状况较差,病情特殊,不宜行腹腔镜手术治疗 7.腹腔镜下肿瘤不可切除的患者 8.严重心理精神疾病 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Clinically and radiologically diagnosed advanced colon tumor at stage IIIC/IV. 2.History of previous abdominal surgery with severe intra-abdominal adhesions. 3.Evident clinical signs of gastrointestinal obstruction at admission. 4.Endocrine system diseases at admission that severely affect blood sugar levels. 5.Severe cardiovascular and cerebrovascular diseases and organ dysfunction at admission. 6.Poor general condition or special circumstances making laparoscopic surgery unsuitable. 7.Patients with unresectable tumors under laparoscopy. 8.Severe psychological or mental disorders. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-07-20 00:00:00至 To 2025-07-20 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-07-20 00:00:00 至 To 2025-07-20 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由专门研究员使用随机数字表生成 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The random method is generated by specialized researchers using a random number table |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
在本实验中,我们采用患者单盲设计,即患者不知道自己被分配到哪一组(FRAS组和ERAS组) 在患者入组后,通过随机数字序列进行分组,将患者分配到FRAS组或ERAS组,患者在入组时不会被告知其具体的分组情况。 由独立的数据收集人员负责采集患者的临床数据和治疗效果评估,这些人员不会参与患者的治疗过程。 统计分析阶段采用终点盲法设计,即负责数据分析的统计人员对患者的具体分组情况保持不知情。 |
|
Blinding: |
In this experiment, we adopted a single-blind design for patients, meaning the patients did not know to which group (FRAS group or ERAS group) they were assigned. After patients were enrolled, they were divided into groups using a random number sequence, assigning them to either the FRAS group or the ERAS group. Patients were not informed of their specific group at the time of enrollment. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
同济大学附属上海市第四人民医院官网 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Shanghai Fourth People's Hospital Affiliated to Tongji University |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集由专人负责通过病例记录表形式记录 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The data collection is handled by a dedicated person and recorded in the form of a case record form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |